The TheraSure-CNI MONITOR test detects gains and losses of larger chromosome segments. Such genomic aberrations occur in most malignant tumors and are often detected in circulating DNA.
We offer the latest diagnostic procedures for early detection of the therapeutic efficacy relating to the drug regimen used to treat each individual patient
Our molecular tests for tumor diseases use cell-free circulating DNA, which is extracted from a blood sample. For this purpose, the blood sampling is drawn into a special tube which is sent to our laboratory.
Using state-of-the-art molecular biology methods, we detect circulating DNA fragments that are released from cancer cells.
The genome of a malignant tumor cell differs as a rule from normal body cells by the loss or gain of larger genomic sections (aberrations) and/or by point mutations.
These genetic changes can be detected from a LIQUID BIOPSY if the circulating tumor DNA is present in the blood at a sufficiently high concentration. We offer the following molecular tests on various clinical questions:
Do you have any questions about our laboratory services, our service and consulting offerings or are you looking for further information? We would like to help you.